Benjamin J. Zeskind Purchases 2,985 Shares of Immuneering Corporation (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind acquired 2,985 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were bought at an average cost of $3.38 per share, with a total value of $10,089.30. Following the transaction, the chief executive officer directly owned 2,305,837 shares of the company's stock, valued at $7,793,729.06. The trade was a 0.13% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Immuneering Stock Performance

Shares of NASDAQ IMRX traded down $0.20 during mid-day trading on Friday, hitting $3.39. 908,546 shares of the stock were exchanged, compared to its average volume of 2,557,943. The company has a market cap of $122.01 million, a P/E ratio of -1.73 and a beta of 0.38. The stock's fifty day simple moving average is $2.00 and its two-hundred day simple moving average is $1.84. Immuneering Corporation has a twelve month low of $1.00 and a twelve month high of $3.87.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). As a group, equities research analysts predict that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Institutional Trading of Immuneering

Several hedge funds have recently modified their holdings of IMRX. HighTower Advisors LLC increased its holdings in shares of Immuneering by 33.7% during the fourth quarter. HighTower Advisors LLC now owns 71,360 shares of the company's stock worth $157,000 after buying an additional 18,000 shares in the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Immuneering during the fourth quarter valued at approximately $390,000. XTX Topco Ltd grew its stake in shares of Immuneering by 177.2% during the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after purchasing an additional 20,871 shares during the last quarter. Marshall Wace LLP bought a new position in Immuneering in the fourth quarter valued at approximately $47,000. Finally, Bridgeway Capital Management LLC boosted its stake in Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after acquiring an additional 22,400 shares during the last quarter. Institutional investors and hedge funds own 67.65% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on IMRX shares. Chardan Capital reissued a "buy" rating and issued a $13.00 price target on shares of Immuneering in a research report on Wednesday, June 18th. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of Immuneering in a research report on Wednesday, June 18th. Mizuho increased their price target on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 18th. Finally, Oppenheimer dropped their price target on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Immuneering currently has an average rating of "Moderate Buy" and an average price target of $13.25.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.